Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4465045
Max Phase: Preclinical
Molecular Formula: C28H27F3N2O7
Molecular Weight: 560.53
Molecule Type: Unknown
Associated Items:
ID: ALA4465045
Max Phase: Preclinical
Molecular Formula: C28H27F3N2O7
Molecular Weight: 560.53
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H]2[C@H]1CC/C(COC(=O)Cn1cc(F)c(=O)n(Cc3ccc(F)cc3F)c1=O)=C\CC[C@@]1(C)O[C@@H]21
Standard InChI: InChI=1S/C28H27F3N2O7/c1-15-19-8-5-16(4-3-9-28(2)24(40-28)23(19)39-26(15)36)14-38-22(34)13-32-12-21(31)25(35)33(27(32)37)11-17-6-7-18(29)10-20(17)30/h4,6-7,10,12,19,23-24H,1,3,5,8-9,11,13-14H2,2H3/b16-4+/t19-,23-,24-,28+/m0/s1
Standard InChI Key: GQHJHWAIPHXCCB-WJWRZYOISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 560.53 | Molecular Weight (Monoisotopic): 560.1770 | AlogP: 2.77 | #Rotatable Bonds: 6 |
Polar Surface Area: 109.13 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.73 | CX LogD: 3.73 |
Aromatic Rings: 2 | Heavy Atoms: 40 | QED Weighted: 0.23 | Np Likeness Score: 0.74 |
1. Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q.. (2019) Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma., 183 [PMID:31553932] [10.1016/j.ejmech.2019.111706] |
Source(1):